Sisi Zheng, MD
Pediatric Hematologist/Oncologist
Professor Scholar at UT Southwestern Medical Center
- Languages Spoken:
- English
Biography
Sisi Zheng, M.D., is a Pediatric Hematologist-Oncologist at Children’s Health℠ and an Assistant Professor in Pediatrics at UT Southwestern Medical Center. Dr. Zheng’s clinical interests include leukemia, bone marrow transplantation, immunology and host defenses.
Dr. Zheng earned her medical degree at Weill Cornell Medical College and subsequently completed her pediatric residency and fellowship training in pediatric hematology-oncology at the Children’s Hospital of Philadelphia. During her fellowship, her research led to the characterization of aberrant splice isoforms that are important to drug resistance against CD22-based immunotherapies.
In addition to treating patients, Dr. Zheng has a passion for research and turning lab discoveries into life-changing patient care. Her laboratory research focuses on understanding how inflammation in the bone marrow environment can facilitate the outgrowth of clonally mutated hematopoietic stem cells (HSCs) and contribute to the early development of myeloid leukemias.
Dr. Zheng is a member of the American Academy of Pediatrics, Children’s Oncology Group, American Society of Hematology and American Association of Cancer Research.
Education and Training
- Medical School
- Weill Cornell Medical College (2014)
- Residency
- Children's Hospital of Philadelphia (2017), Pediatrics
- Fellowship
- Children's Hospital of Philadelphia (2020), Pediatric Hematology/Oncology
- Board Certification
- American Board of Pediatrics/Hematology-Oncology
Conditions
- Iron deficiency anemia
- Sickle cell disease
- Hemoglobinopathy
- Thrombophilia
Departments and Programs
-
Research Interests
- Bone marrow transplantation
- Leukemia
- Immunology and Host defenses
-
Publications
- Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies. Ang Z, Paruzzo L, Hayer KE, Schmidt C, Torres Diz M, Xu F, Zankharia U, Zhang Y, Soldan S, Zheng S, Falkenstein CD, Loftus JP, Yang SY, Asnani M, King Sainos P, Pillai V, Chong E, Li MM, Tasian SK, Barash Y, Lieberman PM, Ruella M, Schuster SJ, Thomas-Tikhonenko A. Blood. 2023 Nov 16;142(20):1724-1739. doi: 10.1182/blood.2023020400. PMID: 37683180
- Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies. Zheng S, Gillespie E, Naqvi AS, Hayer KE, Ang Z, Torres-Diz M, Quesnel-Vallières M, Hottman DA, Bagashev A, Chukinas J, Schmidt C, Asnani M, Shraim R, Taylor DM, Rheingold SR, O'Brien MM, Singh N, Lynch KW, Ruella M, Barash Y, Tasian SK, Thomas-Tikhonenko A. Blood Cancer Discov. 2022 Mar 1;3(2):103-115. doi: 10.1158/2643-3230.BCD-21-0087. PMID: 35015683
- Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Asnani M, Hayer KE, Naqvi AS, Zheng S, Yang SY, Oldridge D, Ibrahim F, Maragkakis M, Gazzara MR, Black KL, Bagashev A, Taylor D, Mourelatos Z, Grupp SA, Barrett D, Maris JM, Sotillo E, Barash Y, Thomas-Tikhonenko A. Leukemia. 2020 Apr;34(4):1202-1207. doi: 10.1038/s41375-019-0580-z. Epub 2019 Oct 7. PMID: 31591467
- Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors. Zheng S, Asnani M, Thomas-Tikhonenko A. Cancer J. 2019 May/Jun;25(3):217-222. doi: 10.1097/PPO.0000000000000381. PMID: 31135529
-
Professional Activities
- American Academy of Pediatrics
- Children’s Oncology Group
- American Society of Hematology
- American Association of Cancer Research
